Thus, the downregulation of DACT3-AS1 in gastric cancer not only promotes tumor progression but also facilitates the development of resistance to oxaliplatin, highlighting its dual role in both tumor biology and chemoresistance. Here, DACT3 is linked to gastric cancer.